Adjuvant immunotherapy for melanoma patients: progress and opportunities.

ESMO Open · 2024 · PMC11040594 · PMID 38626633

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In a subgroup analysis, the HR for RFS was 0.38 (0.11-1.31); although for stage IIIA patients the RFS was numerically higher with anti-PD-1 in the adjuvant setting, the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.